After decades of racing to the bottom on pricing, a revolution is coming to the U.S. generics market, writes Yaral Pharma CEO ...

Advocacy for alternatives to animal testing in clinical research is pushing the industry away from animal-based endotoxin ...

Experts at Faegre Drinker offer life sciences business planning and risk mitigation strategies to consider in response to ...

Modern drug development approaches that integrate functional plans with larger business goals are needed for success in early ...

Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...

They say the mark of intelligence is making the complex simple. By that standard, navigating early commercialization in the pharmaceutical industry is one of the toughest challenges, especially for ...

In the realm of pharmaceutical patent litigation, settlement agreements between branded and generic pharmaceutical companies are frequently used to resolve disputes before, during, and after trials in ...

In the early 1990s, my grandmother’s health and cognitive abilities started to decline rapidly. She showed clear signs of dementia, which was most likely Alzheimer’s disease but never received a ...

There are lots of reasons why physicians and patients (and payers) might prefer one drug over another for the treatment of a given disease. Efficacy and safety are paramount, of course, but there are ...

Earnouts have been a part of M&A for decades, with pharmaceutical M&A transactions in particular relying on them. These earnout provisions are typically referred to as “milestone payments” because ...

In recent years, oncology trials have surged, yet the integration of electronic patient-reported outcomes (ePROs) remains surprisingly low, with only 8.3% of FDA-approved oncology drugs from 2010 to ...

Electronic Clinical Outcome Assessments (eCOAs) have advanced considerably, yet persistent myths still prevent clinical teams from leveraging their full value. As regulatory expectations evolve and ...